Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The decisions patients and their doctors make about which treatment to select as first-line therapy for localized prostate cancer are commonly based on perceptions and expectations about the side effects of these treatments, as well as on the curative potential of the therapy.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: comparison, first line, HRQOL, outcomes, quality of life, Treatment | Leave a Comment »
It is well understood that skeletal complications are a crucial factor in the quality of life and the prognosis of patients with hormone-refractory prostate cancer (HRPC); however, their true prevalence and impact on the prognosis remain largely unknown.
Filed under: Management, Treatment | Tagged: bone pain, complications, hormone-refractoery prostate cancer, HRPC, skeletal | Leave a Comment »
The gold standard treatment for clinical stage T3 prostate cancer has long been the combination of radiotherapy and extended hormone therapy. However, the accuracy of clinical staging based on DRE is open to some question, since 20 percent of patients assessed to have cT3 prostate cancer today appear to be over-staged during physical examination.
Filed under: Management, Treatment | Tagged: cT3 disease, Europe, surgical treatment | Leave a Comment »
Michalski et al. have published consensus guidelines from a Radiation Therapy Oncology Group (RTOG) committee on the appropriate clinical target volume of the prostate fossa (PF-CTV) for post-surgical, conformal radiation therapy for prostate cancer.
Filed under: Management, Treatment | Tagged: guideline, post-surgery, radiation | Leave a Comment »
The Canary Foundation and Stanford University Medical Center have today announced their joint commitment of $20 million to create the Canary Center at Stanford for Cancer Early Detection, a world-class research center dedicated to improving cancer early detection.
Filed under: Diagnosis, Risk | Tagged: Canary Foundation, early detection, Stanford | Leave a Comment »
The American Urological Association (AUA) has just published its June issue of AUA News complete with various “take home ” messages on prostate cancer from the annual meeting at the end of April.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: AUA News | Leave a Comment »
Over the years, prostate cancer patients (and other types of patients too) have often sought out practitioners of types of health care considered to be “unconventional” by many in the academic and mainstream “Western” medical community.
Filed under: Management, Prevention, Treatment | Tagged: integrative, medicine | Leave a Comment »
Today’s news reports deal with items on: The mechanism of action of D,L-sulforaphane Isolation of an active protein from the bitter melon plant The potential of focal therapy for localized prostate cancer Reconstruction of the lower urinary tract after radical prostatectomy Hypofractionated intensity-modulated arc radiotherapy in N1 prostate cancer
Filed under: Drugs in development, Management, Prevention, Treatment | Tagged: arc, bitter melon, focal therapy, hypofractionated, intensity-modulated, radiotherapy, reconstruction, sulforaphane, urinary tract | Leave a Comment »
Many prostate cancer patients are advised to use bisphosphonate therapy to prevent bone loss and other bone-related adverse events associated with long-term hormonal therapy. A disorder now known as bisphosphonate-related osteonecrosis of the jaw (BRONJ) was initially associated with bisphosphonate therapy in 2003-04 and there has been extensive research on this relationship since that date.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: bisphosphonate, jaw, osteonecrosis | 2 Comments »
Two days ago someone left us a message about a new web site called HIFUcertified.com. We looked briefly at a couple of pages of the site and learned very little. “That’s interesting,” we thought. “Who’s certifying these specialists? And what does ‘certified’ mean?” So we responded to the e-mail address provided (info@hifucertified.com) and asked for [...]
Filed under: Tips | Tagged: HIFU, HIFUcertified.com, scam | Leave a Comment »
Today’s news reports deal with: Diabetes, PSA, and prostate cancer risk Magnetic resonance spectroscopic imaging Ongoing trials of dutasteride as early stage treatment for prostate cancer
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: ARTS, diabetes, dutasteride, magmentic resonance spectroscopic imaging, MSRI, REDEEM, risk | Leave a Comment »
Today’s news reports refer to a series of reviews that appeared this month in a supplement to Urology as well as other articles: 20 years of experience with the PSA test in assessment of risk for prostate cancer Biomarkers in the assessment of future risk for prostate cancer Treatment choice, outcome, and quality of life [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: biomarkers, choice, Diagnosis, outcome, prognosis, PSA, quality of life, risk, survival, Treatment | Leave a Comment »
Angela Jenkins, one of the founders of Prostate Cancer International, posted this tale on The “New” Prostate Cancer Social Network early this morning …
Filed under: Diagnosis, Prevention, Risk | Tagged: mouse, risk, testing | 1 Comment »
A German group has recently published data from another randomized clinical trial of adjuvant external beam radiotherapy (EBRT) in patients shown to have extraprostatic disease after radical prostatectomy (RP), as compared to a “wait and see” or “watchful waiting” strategy.
Filed under: Management, Treatment | Tagged: radical prostatectomy, radiotherapy | Leave a Comment »
In the chaos of the ASCO annual meeting we had forgotten to point out that June is Men’s Health Month here in America as we lead up to Father’s Day on June 21.
Filed under: Diagnosis, Living with Prostate Cancer, Prevention, Risk | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site